Institute for Gene Therapies
The Institute for Gene Therapies (IGT) advocates for modernized policies that encourage transformative gene therapies, promotes patient access, and codifies transparent reimbursement practices. It aims to educate stakeholders about the potential of gene therapy, address regulatory and reimbursement hurdles, and ensure a greater understanding of the value gene therapies bring to patients, families, and society. IGT is committed to modernizing the healthcare system to fully realize the potential of gene therapies, which are changing the future of human health by targeting the cause of diseases at the genetic level with long-lasting benefits.
Industries
Nr. of Employees
small (1-50)
Institute for Gene Therapies
Washington, District of Columbia, United States, North America
Products
Policy comment letters and whitepapers
Formal submissions and written analyses addressing federal proposed rules, RFIs, and policy proposals related to gene- and cell-therapy access, reimbursement, and regulation.
Educational resources on gene therapy
Introductory and explanatory materials covering gene therapy basics, disease areas under study, and distinctions between gene therapy and gene editing.
Policy comment letters and whitepapers
Formal submissions and written analyses addressing federal proposed rules, RFIs, and policy proposals related to gene- and cell-therapy access, reimbursement, and regulation.
Educational resources on gene therapy
Introductory and explanatory materials covering gene therapy basics, disease areas under study, and distinctions between gene therapy and gene editing.
Services
Advocacy with federal agencies and Congress on regulatory, reimbursement, and programmatic issues affecting gene and cell therapies; preparation and submission of comment letters and policy proposals.
Creating and distributing educational content explaining gene therapy science, clinical differences from traditional medicines, and system-level implications for payers and providers.
Organizing congressional briefings, panel discussions, and roundtables to present scientific, clinical, and patient perspectives on access and policy for gene therapies.
Managing corporate, scientific/academic/medical, and patient advisory councils to gather expert input and align policy priorities across stakeholders.
Advocacy with federal agencies and Congress on regulatory, reimbursement, and programmatic issues affecting gene and cell therapies; preparation and submission of comment letters and policy proposals.
Creating and distributing educational content explaining gene therapy science, clinical differences from traditional medicines, and system-level implications for payers and providers.
Organizing congressional briefings, panel discussions, and roundtables to present scientific, clinical, and patient perspectives on access and policy for gene therapies.
Managing corporate, scientific/academic/medical, and patient advisory councils to gather expert input and align policy priorities across stakeholders.
Expertise Areas
- Regulatory policy for cell and gene therapies
- Reimbursement policy and value assessment for transformative therapies
- Patient advocacy and stakeholder engagement
- Public affairs and government relations
Key Technologies
- Viral vector-mediated gene delivery
- Gene editing (genome modification techniques)
- Cell and gene therapy clinical and regulatory development pathways
- Customized bioprocessing and manufacturing approaches for gene therapies
News & Updates
On June 17, the Institute for Gene Therapies (IGT), in partnership with the Alliance for Regenerative Medicine (ARM), convened a panel...
Amanda Moore is a devoted mother, advocate, and CEO of the Angelman Syndrome Foundation. After adopting her two sons, Jackson and Baden,...
Lesa Brackbill is a passionate mother, advocate, author, and member of IGT’s Patient Advocacy Advisory Council. After her daughter...
Authors: IGT Chairman Erik Paulsen, Scientific Academic and Medical Council Chair Donna Christian-Christensen, M.D. As our nation’s...
As we commemorate the fifth anniversary of the Institute for Gene Therapies (IGT) today, I want to take a look back at the strides we've...
IGT leaders recently penned a piece exploring the strides being made in gene therapy and highlighting the ongoing challenges that must be...
On June 17, the Institute for Gene Therapies (IGT), in partnership with the Alliance for Regenerative Medicine (ARM), convened a panel...
Amanda Moore is a devoted mother, advocate, and CEO of the Angelman Syndrome Foundation. After adopting her two sons, Jackson and Baden,...
Lesa Brackbill is a passionate mother, advocate, author, and member of IGT’s Patient Advocacy Advisory Council. After her daughter...
Authors: IGT Chairman Erik Paulsen, Scientific Academic and Medical Council Chair Donna Christian-Christensen, M.D. As our nation’s...
As we commemorate the fifth anniversary of the Institute for Gene Therapies (IGT) today, I want to take a look back at the strides we've...
IGT leaders recently penned a piece exploring the strides being made in gene therapy and highlighting the ongoing challenges that must be...